RxDoctor Payments DataLook up a doctor →

Patrick Annello, MD

Anesthesiology · Roslyn, NYNPI 1508066259

Payments from drug & device makers

$20,126in general payments, 2019–2025

Across 740 payments — averaging $27.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertex$7K
  • AbbVie$3K
  • Abbott$2K
  • Scilex Pharmaceuticals Inc.$1K
  • Collegium Pharmaceutical, Inc.$823
  • Pfizer$560
  • plus $6K from 48 others

What the payments were for

  • Consulting fees$5,18326%
  • Travel & lodging$1,1986%
  • Food & beverage$13,74568%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,126 in reported general payments places this provider in the 95th percentile of 4,157 anesthesiology providers in New York.

See all anesthesiology providers in New York

Medicare billing

Part B allowed, 2024
$574,127
Medicare patients
986
Services billed
8,655

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Levorphanol Tartrate23$65,721
Nucynta ErTapentadol Hcl32$43,509
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen241$37,528
MovantikNaloxegol Oxalate58$23,073
OxycontinOxycodone Hcl31$21,352
NucyntaTapentadol Hcl14$14,917
BelbucaBuprenorphine Hcl21$13,375
Xtampza ErOxycodone Myristate29$12,249
ZtlidoLidocaine11$9,592
Oxycodone Hcl268$7,431
BelsomraSuvorexant16$6,857
Fentanyl44$5,861
Lidocaine42$5,191
Lubiprostone24$4,459
Pregabalin86$3,997

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta Er, Nucynta, Belbuca, Xtampza Er$823$84,05096 claims
Virtus Pharmaceuticals LLCLevorphanol Tartrate$190$65,72123 claims
Redhill Biopharma Inc.Movantik$191$23,07358 claims
Scilex Pharmaceuticals Inc.Ztlido$1,372$9,59211 claims
MerckBelsomra$40$6,85716 claims
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate$32$4,30040 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,157 anesthesiology providers in New York.

Other anesthesiology in Roslyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →